Esperion Therapeutics Inc. (ESPR) Breaks into New 52-Week High on March 20 Session

Equities Staff |

Shares of Esperion Therapeutics Inc. (ESPR) broke into a new 52-week high yesterday, hitting a peak of $42.59. Shares closed at $41.22 after opening at $32.10 for a move of 74.14%. The company now has a market cap of $929.76 million.

Investors and traders can learn a lot about a stock’s momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Esperion Therapeutics Inc., the new 52-week high came on volume of 30.42 million. The stock has a float of 22.56 million shares and average daily volume of $711,771. It has a 50-day SMA of $20.31 and a 200-day SMA of $14.32.

For a complete fundamental analysis analysis of Esperion Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for ESPR.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Inc. is based out of Ann Arbor, MI and has some 44 employees. Its CEO is Timothy M. Mayleben.

Esperion Therapeutics Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Esperion Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ESPR’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Goldrea Resources Corp.

Goldrea Resources Corp is engaged in the acquisition, exploration and development of mineral properties located in North America.

Private Markets

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…